Moderna, Inc. (MRNA) Stock Analysis
A live, multi-source view of Moderna, Inc. (MRNA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 4,700 employees · modernatx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Moderna, Inc. (MRNA) had a market capitalization of $58.11B (forward -31.7) and a beta of 1.11; the shares traded in a 52-week range of $22.28 – $176.66 (499.6% over the year).
- Market cap
- $58.11B
- Enterprise value
- $54.26B
- Forward P/E
- -31.7
- Price / book
- 8.59
- EPS (trailing)
- $-7.98
- EPS (forward)
- $-4.59
- Payout ratio
- 0.0%
- 52-week range
- $22.28 – $176.66
- 52-week change
- 499.6%
- Beta
- 1.11
- Average volume
- 15.8M
- Shares outstanding
- 399.2M
- Short % of float
- 16.16%
- Profit margin
- -141.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Moderna, Inc. (MRNA) last closed at $136.62 (the last completed close before that scan).
Technicals at the scan: RSI 59 (neutral territory), price +5.6% versus its 20-day average, 20-day versus 50-day average spread +44.4%, MACD histogram -2.54.
Sentiment inputs: 64% of recent Finnhub-scored headlines read bullish; StockTwits 64% bullish; Reddit mentions -83% over 24 hours; analyst consensus score 53/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 1 sell of MRNA; corporate insiders filed 0 buys and 5 sells (3 distinct filers, latest disclosure 2026-09-09). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Stephane Bancel (0B/4S), Maria Elvira Salazar (1B/1S), Shannon Thyme Klinger (0B/1S). Who is trading what
RapidTradeView pick record
MRNA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Moderna, Inc. (MRNA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MRNA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.